Parkinson and the Males Body Composition (PD&MBC)

May 15, 2025 updated by: Luis Santos, University of Oviedo

Parkinson´s Disease: Correlation Analysis Between the Cardinal Motor Symptoms of the Illness and the Male Patients´ Body Composition

The main aim of the present study was to ascertain the type of relationship (dependency or independency) among some of the cardinal motor symptoms of the Parkinson´s disease (PD) and the body composition (BC) variables of a group of the male PD´s patients, using the bioelectrical impedance analysis.

Study Overview

Status

Completed

Study Type

Observational

Enrollment (Actual)

15

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Oviedo, Spain, 33007
        • University of Oviedo

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

A group of fifteen male patients with idiopathic Parkinson´s disease participated in the project.

Description

Inclusion Criteria:

(I) Males with diagnosis of idiopathic PD and rated 1-3 on the Hoehn and Yahr Scale.

(II) No type of dementia as assessed by the mini-mental state examination. (III) Between 50 and 69 years old (a specific range of ages of the illness´s onset).

(IV) Between one and five years diagnosed with the illness. (V) Able to stand for two min without assistance. (VI) Able to walk teen m without assistance.

Exclusion Criteria:

(I) Do not meet the eligibility criteria. (II) Suffer a neurological disease other than Parkinson´s disease.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Patients
The patients were assigned to the same group because the study´s design only demands to create one group of patients.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The body composition variables or the bioelectrical impedance variables
Time Frame: From February 2025 to February 2025
weight (kg), fat-free mass in absolute terms (FFMa) (kg), fat-free mass in relative terms (FFMr) (normalized per kg of body mass -kg/kg of body weight-), fat-free mass of the right arm (FFMRA) (kg), fat-free mass of the left arm (FFMLA) (kfg), difference between the FFMRA and the FFMLA (%), fat-free mass of the right leg (FFMRL) (kg), fat-free of the mass left leg (FFMLL) (kg), difference between the FFMRL and the FFMLL (%), body fat mass (BFM) (kg), skeletal muscle mass (SMM) (kg), body mass index (BMI) (kg/m2), percentage body fat (PBF) (%), total body water in absolute terms (TBWa) (L), total body water in relative terms (TBWr) (normalized per kg of body mass -kg/kg of body weight-), total water of the right arm (TWRA) (L), total water of the left arm (TWLA) (L), difference between the TWRA and the TWLA (%), total water of the right leg (TWRL) (L), total water of the left leg (TWLL) (L), difference between the TWRL and the TWLL (%), intracellular water (ICW) (L), extracellular
From February 2025 to February 2025
The Movement Disorder Society-Unified Parkinson´s Disease Rating Scale (MDS-UPDRS))
Time Frame: From February 2025 to February 2025
MDS-UPDRS: Spanish validated version of the MDS-UPDRS. The possible score ranges from 0 to 72 points whereby 0 points represent a healthy status and the more points, the worse health status.
From February 2025 to February 2025
The Ten-Meter Walk Test
Time Frame: From February 2025 to February 2025
The Ten-Meter Walk Test: performance measure used to assess walking speed in meters per second over a short distance (10 meters).
From February 2025 to February 2025
Step length
Time Frame: From February 2025 to February 2025
The step length of the patients will be determined using kinematic gait analysis during the TMWT, utilizing the OptoGait system (Microgait, Optogait, v.1.12.21, Italy). The step length of the patients will be determined in cm. This system consists of transmitter and receiver bars equipped with optical sensors operating at a frequency of 1000 Hz, which will be positioned along the ten-meter walking corridor, from meter two to meter seven.
From February 2025 to February 2025
: Spanish validated version of the Disability of the Arm, Shoulder and Hand (DASH)
Time Frame: From February 2025 to February 2025
DASH: Spanish validated version of the Disability of the Arm, Shoulder and Hand. The possible score ranges from 0 (which means no disability) to 100 (which means most severe disability). Higher scores indicate a greater level of disability and severity, whereas, lower scores indicate a lower level of disability.
From February 2025 to February 2025
The Timed up and Go Test (TUG)
Time Frame: From February 2025 to February 2025
TUG: The TUG measures of functional mobility that was initially developed to identify mobility and balance impairments. Participants takes to rise from a chair, walk three meters, turn around 180 degrees, walk back to the chair, and sit down while turning 180 degrees, as fast as they can (the time of the test is determined in sec).
From February 2025 to February 2025
Handgrip Strength of both hands.
Time Frame: From February 2025 to February 2025
Handgrip Strength of both hands: manual dynamometer measured in kilograms.
From February 2025 to February 2025
Static posturography
Time Frame: From February 2025 to February 2025
Static posturography, assessed by measurement of the center of pressure (CoP). These CoP parameters; Length, in mm, Area in mm2 and Speed, Xspeed and Yspeed in m/s will be combined to report the patient´s static posturography.
From February 2025 to February 2025
The nine holes peg test (9-HPT)
Time Frame: From February 2025 to February 2025
The nine holes peg test (9-HPT) is a brief, standardized, quantitative test of upper extremity function. Both the dominant and non-dominant hands are tested twice. The patient is seated at a table with a small, shallow container holding nine pegs and a wood or plastic block containing nine empty holes. On a start command when a stopwatch is started, the patient picks up the nine pegs one at a time as quickly as possible, puts them in the nine holes, and, once they are in the holes, removes them again as quickly as possible one at a time, replacing them into the shallow container. The total time to complete the task is recorded in minutes. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The score for the 9-HPT is an average of the four trials. The two trials for each hand are averaged, converted to the reciprocals of the mean times for each hand and then the two reciprocals are averaged.
From February 2025 to February 2025

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2024

Primary Completion (Actual)

February 3, 2025

Study Completion (Actual)

February 28, 2025

Study Registration Dates

First Submitted

December 3, 2024

First Submitted That Met QC Criteria

December 3, 2024

First Posted (Actual)

December 9, 2024

Study Record Updates

Last Update Posted (Actual)

May 18, 2025

Last Update Submitted That Met QC Criteria

May 15, 2025

Last Verified

May 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ETICA-ULE-081-2024

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Neurodegenerative Disease

Subscribe